The incidence of melanoma in the United States is increasing at the highest rate for any form of cancer. The current lifetime risk of developing melanoma in the U.S. is 1 in 68. At present, there are few effective systemic therapies to treat advanced stages of melanoma and the key to improved survival in all affected individuals remains early diagnosis and treatment. We recently identified the transcriptional regulatory protein Id1 as being a repressor of the p16/Ink4a familial melanoma gene and hypothesized that Id1 upregulation could play a key role in regulating p16 expression during the development or progression of melanomas. Our evaluations of Id1 expression in melanocytic lesions at various stages of malignant progression have allowed us to identify Id1 as a potential marker of the earliest identifiable cases of melanomas, melanoma-in-situ. Based on our preliminary data in the melanoma cases studied to date, we propose a series of experiments to elucidate the precise role of Id1 in the development of human melanomas.
Our specific aims are therefore: 1) To determine the significance of Id1 expression in melanocytic lesions and its utility as a diagnostic and prognostic indicator of malignancy. We will develop a rapid, sensitive, and specific technique for in-situ detection of Id1 expression in melanocytic lesions and perform large-scale analysis of Id1 expression in archival tissue specimens; 2) To determine the effect of Id1 gene expression on the growth and differentiation of primary human melanocytes and melanoma cell lines and investigate the effect of loss of ld1 expression on melanoma cell growth and differentiation; 3) To identify downstream effectors of Id1 in primary human melanocytes using gene expression profiling. The long-term goals of this study are to determine the role of Id1 in the development and/or progression of human melanomas. We will evaluate Id1 as a marker for early disease and its utility as a diagnostic and/or prognostic indicator of melanoma. Ultimately we hope to use this molecular characterization of the role of Id1 in melanoma development to design targeted treatment strategies for this notorious malignancy.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Research Project (R01)
Project #
5R01CA107017-02
Application #
6866707
Study Section
Special Emphasis Panel (ZRG1-CBSS (01))
Program Officer
Thurin, Magdalena
Project Start
2004-04-01
Project End
2009-03-31
Budget Start
2005-04-01
Budget End
2006-03-31
Support Year
2
Fiscal Year
2005
Total Cost
$257,513
Indirect Cost
Name
Johns Hopkins University
Department
Internal Medicine/Medicine
Type
Schools of Medicine
DUNS #
001910777
City
Baltimore
State
MD
Country
United States
Zip Code
21218
Yan, Gai; Eller, Mark S; Elm, Courtney et al. (2013) Selective inhibition of p300 HAT blocks cell cycle progression, induces cellular senescence, and inhibits the DNA damage response in melanoma cells. J Invest Dermatol 133:2444-2452
Rushing, Erica C; Stine, Megan J; Hahn, Sarah J et al. (2012) Neuropilin-2: a novel biomarker for malignant melanoma? Hum Pathol 43:381-9
Stine, Megan J; Wang, C Joanne; Moriarty, Whei F et al. (2011) Integration of genotypic and phenotypic screening reveals molecular mediators of melanoma-stromal interaction. Cancer Res 71:2433-44
Ryu, Byungwoo; Moriarty, Whei F; Stine, Megan J et al. (2011) Global analysis of BRAFV600E target genes in human melanocytes identifies matrix metalloproteinase-1 as a critical mediator of melanoma growth. J Invest Dermatol 131:1579-83
Cummings, Staci D; Ryu, Byungwoo; Samuels, Michael A et al. (2008) Id1 delays senescence of primary human melanocytes. Mol Carcinog 47:653-9
Ryu, Byungwoo; Kim, Dave S; DeLuca, Amena M et al. (2007) Id1 expression is transcriptionally regulated in radial growth phase melanomas. Int J Cancer 121:1705-9
Fecher, Leslie A; Cummings, Staci D; Keefe, Megan J et al. (2007) Toward a molecular classification of melanoma. J Clin Oncol 25:1606-20
Ryu, Byungwoo; Kim, Dave S; Deluca, Amena M et al. (2007) Comprehensive expression profiling of tumor cell lines identifies molecular signatures of melanoma progression. PLoS One 2:e594
Alani, Rhoda M; Silverthorn, Courtney F; Orosz, Kate (2004) Tumor angiogenesis in mice and men. Cancer Biol Ther 3:498-500